Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$2.27
-1.7%
$2.15
$1.30
$13.20
$2.99M0.54639,468 shs54,152 shs
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
$1.01
-8.3%
$1.64
$0.99
$10.89
$4.70M1.14374,155 shs65,450 shs
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
$0.20
-8.5%
$0.29
$0.18
$2.77
$2.52M0.63152,031 shs141,284 shs
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$5.46
-8.8%
$0.40
$0.10
$6.74
$423.91M0.772.19 million shs161,505 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-0.43%-7.23%+9.48%+1.32%-72.85%
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
-8.20%-8.94%-33.73%-64.84%-65.00%
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
+0.76%-1.39%-24.23%-46.75%-90.74%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00%0.00%0.00%0.00%+2,439.53%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.3762 of 5 stars
3.32.00.00.02.90.00.6
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
N/AN/AN/AN/AN/AN/AN/AN/A
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
1.2764 of 5 stars
3.53.00.00.00.00.80.6
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.50
Moderate Buy$11.00384.58% Upside
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
N/AN/AN/AN/A
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
3.00
Buy$1.00412.82% Upside
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/A

Current Analyst Ratings

Latest HCTI, VBLT, CYCC, and LUCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $11.00
3/26/2024
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1.75 ➝ $1.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$420K7.12N/AN/A$0.57 per share3.98
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
$33.20M0.14N/AN/A$0.12 per share8.42
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
$1.15M2.19N/AN/A$0.43 per share0.45
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$660K642.29N/AN/A$0.32 per share17.06

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/14/2024 (Confirmed)
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
-$12.34M-$2.94N/AN/A-37.16%-205.49%-83.03%5/14/2024 (Estimated)
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
-$6.66MN/A0.00N/A-578.05%-99.83%-92.59%6/24/2024 (Estimated)
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
-$32.30M-$0.21N/AN/AN/A-73.45%-54.11%N/A

Latest HCTI, VBLT, CYCC, and LUCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$4.93N/A+$4.93N/AN/AN/A  
3/25/2024Q4 2023
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
N/A-$0.19-$0.19-$0.19N/A$0.62 million
3/19/2024Q4 2023
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$6.35-$6.23+$0.12-$6.23N/A$0.03 million
3/18/2024Q4 2023
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
N/A-$1.26-$1.26-$1.26N/A$7.06 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
N/AN/AN/AN/AN/A
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
N/AN/AN/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
0.91
0.91
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
1.65
0.71
0.71
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
N/A
9.00
7.63
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/A
4.63
4.63

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
0.33%
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
0.96%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.96%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2,0181.32 million1.21 millionOptionable
Healthcare Triangle, Inc. stock logo
HCTI
Healthcare Triangle
314.65 million4.53 millionNot Optionable
Innovative Eyewear, Inc. stock logo
LUCY
Innovative Eyewear
1112.93 million11.50 millionNot Optionable
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
777.64 million72.88 millionOptionable

HCTI, VBLT, CYCC, and LUCY Headlines

SourceHeadline
AlboGraft Polyester Vascular Graft from LeMaitreAlboGraft Polyester Vascular Graft from LeMaitre
news-medical.net - May 7 at 5:33 PM
Tommy Garten elected to VBL Hall of FameTommy Garten elected to VBL Hall of Fame
therecorderonline.com - March 28 at 1:31 PM
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
nature.com - February 21 at 3:29 PM
Vascular News and ResearchVascular News and Research
news-medical.net - November 25 at 2:28 PM
Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26
msn.com - November 3 at 12:39 AM
Notable Labs Closes Merger Transaction With VBL TherapeuticsNotable Labs Closes Merger Transaction With VBL Therapeutics
finance.yahoo.com - October 16 at 3:55 PM
VBL Therapeutics Announces Results of Annual and Special Shareholder MeetingVBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
finance.yahoo.com - October 12 at 3:13 PM
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
finance.yahoo.com - October 4 at 8:40 AM
Vascular Biogenics Rises on Presentation HypeVascular Biogenics Rises on Presentation Hype
finance.yahoo.com - September 9 at 12:00 PM
VBLT Stock Sees Decline of Approximately -0.22% in Last Five DaysVBLT Stock Sees Decline of Approximately -0.22% in Last Five Days
knoxdaily.com - September 7 at 9:15 PM
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
finance.yahoo.com - September 6 at 7:30 PM
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
businesswire.com - August 28 at 7:00 PM
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
businesswire.com - August 28 at 3:04 PM
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - August 14 at 8:09 AM
Monitoring Vascular Biogenics Ltd. (VBLT) after recent insider movementsMonitoring Vascular Biogenics Ltd. (VBLT) after recent insider movements
knoxdaily.com - July 26 at 4:10 PM
Vascular Biogenics (NASDAQ: VBLT)Vascular Biogenics (NASDAQ: VBLT)
fool.com - July 23 at 5:52 PM
Recent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)Recent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)
knoxdaily.com - July 12 at 4:20 PM
VBLT Stock Sees Decline of Approximately -4.31% in Last Five DaysVBLT Stock Sees Decline of Approximately -4.31% in Last Five Days
knoxdaily.com - July 7 at 2:11 PM
Days-to-cover ratio for VBLT surges to 0.84 due to rise in short interestDays-to-cover ratio for VBLT surges to 0.84 due to rise in short interest
knoxdaily.com - June 23 at 8:26 PM
The Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular SurgeryThe Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgery
medscape.com - May 18 at 1:35 AM
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 8:03 PM
Developing a Patient-Centered Approach to Vascular Access Device SelectionDeveloping a Patient-Centered Approach to Vascular Access Device Selection
medscape.com - May 10 at 8:52 AM
CADASIL: The Most Common Hereditary Subcortical Vascular DementiaCADASIL: The Most Common Hereditary Subcortical Vascular Dementia
medscape.com - May 5 at 1:05 AM
Aspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular DiseaseAspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Disease
medscape.com - May 2 at 8:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cyclacel Pharmaceuticals logo

Cyclacel Pharmaceuticals

NASDAQ:CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Healthcare Triangle logo

Healthcare Triangle

NASDAQ:HCTI
Healthcare Triangle, Inc., a healthcare information technology company, focuses on developing solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record, and healthcare and life sciences industry. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to evidence, and accelerate their digital transformation. The company's software platforms include CloudEz, an enterprise multi-cloud transformation and management platform that enables customers to manage their cloud infrastructure in private, hybrid, and public cloud infrastructures; and DataEz, a cloud-based data analytics and data science platform for the data analytics and data science requirements of life sciences/pharmaceutical and healthcare provider organizations. It also provides Readabl.AI, a Software-as-a-Service solution that uses public cloud artificial intelligence and machine learning to recognize and extract healthcare information from documents, faxes, and narrative reports. In addition, the company offers cloud IT services; and healthcare IT services, such as electronic health records and software implementation, optimization, and extension to community partners, as well as application managed services, and backup and disaster recovery on public cloud. It primarily serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers. The company was incorporated in 2019 and is based in Pleasanton, California. Healthcare Triangle, Inc. operates as a subsidiary of SecureKloud Technologies, Inc.
Innovative Eyewear logo

Innovative Eyewear

NASDAQ:LUCY
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.
Vascular Biogenics logo

Vascular Biogenics

NASDAQ:VBLT
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.